Nuvalent (NUVL) announced that the first patient has been dosed in Alkazar, the company’s global Phase 3 randomized, controlled trial evaluating neladalkib for TKI-naive patients with advanced ALK-positive non-small cell lung cancer, versus Alecensa, a front-line standard of care.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
- Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
- Nuvalent price target raised to $112 from $105 at Baird
- Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
- Nuvalent price target raised to $140 from $125 at Leerink